Serum irisin level in myocardial infarction patients with or without heart failure

El-Mottaleb, Nashwa A. Abd; Galal, Heba M.; Maghraby, Khaled El; Gadallah, Aml Ibrahim

doi:10.1139/cjpp-2018-0736

Cited by 34 publications

(27 citation statements)

References 54 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In heart, irisin improving mitochondrial functions protects cardiomyoblasts from various injuries characterized by elevated ROS production, i.e., ischemic and reperfusion [143], high glucose-induced [144], and lipotoxic-induced injury [145]. Moreover, human different reports have shown that irisin levels were lower in the diabetic patients with cardiovascular complications [146] and in subjects with myocardial infarction or heart failure [147]. Finally, in a mouse model of cardiac ischemia, irisin treatment reduces infarct size, promotes neo angiogenesis, and enhances the reestablishment of cardiac function [148].…”

Section: Irisin: Biological Rolementioning

confidence: 99%

Adipokines, Myokines, and Cardiokines: The Role of Nutritional Interventions

Senesi

Luzi

Terruzzi

2020

IJMS

View full text Add to dashboard Cite

: It is now established that adipose tissue, skeletal muscle, and heart are endocrine organs and secrete in normal and in pathological conditions several molecules, called, respectively, adipokines, myokines, and cardiokines. These secretory proteins constitute a closed network that plays a crucial role in obesity and above all in cardiac diseases associated with obesity. In particular, the interaction between adipokines, myokines, and cardiokines is mainly involved in inflammatory and oxidative damage characterized obesity condition. Identifying new therapeutic agents or treatment having a positive action on the expression of these molecules could have a key positive effect on the management of obesity and its cardiac complications. Results from recent studies indicate that several nutritional interventions, including nutraceutical supplements, could represent new therapeutic agents on the adipo-myo-cardiokines network. This review focuses the biological action on the main adipokines, myokines and cardiokines involved in obesity and cardiovascular diseases and describe the principal nutraceutical approaches able to regulate leptin, adiponectin, apelin, irisin, natriuretic peptides, and follistatin-like 1 expression.

show abstract

Section: Irisin: Biological Rolementioning

confidence: 99%

Adipokines, Myokines, and Cardiokines: The Role of Nutritional Interventions

Senesi

Luzi

Terruzzi

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…El-Mottaleb NA et al found irisin to be a useful biomarker in the diagnosis of myocardial infarction with or without heart failure [9]. The authors evaluated eighty-six subjects (33 patients with myocardial infarction, 33 patients with myocardial infarction and heart failure, and 20 controls) and found negative correlations between irisin and BMI, WHR, SBP, DBP, troponin-I, CK-MB, TNF-α, TC, TGs, and LDL-C.…”

Section: Discussionmentioning

confidence: 99%

“…The blood concentration of irisin is significantly altered in patients suffering from acute coronary syndrome, especially in myocardial infarction (AMI), ST-Elevation Myocardial Infarction (STEMI) and stable coronary disease. Irisin seems to be a clinically promising marker reflecting cardiovascular system efficiency and the metabolic condition of the entire body of patients with CHF [8,9]. BIA as a non-invasive method reliably evaluates body composition and its nutritional status at the cellular level.…”

Section: Introductionmentioning

confidence: 99%

Electrical and Hormonal Biomarkers in Cachectic Elderly Women with Chronic Heart Failure

Sobieszek

Powrózek

Mazurek

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Cachexia is an unfavorable metabolic syndrome causing involuntary weight loss followed by muscle wasting, which can lead to the exacerbation of chronic heart failure (CHF), and considerably increases mortality rate among CHF patients. Unfortunately, until now it has not been possible to determine factors that could improve clinical options for cachexia management or enable the identification of patients at risk of its development. We assessed how cachexia conditions in CHF reflect cardiac and laboratory parameters in comparison with non-cachectic patients. Methods: 66 women were enrolled to the study group and underwent meticulous screening, according to recent clinical guidelines, in order to enable CHF and cachexia detection. Body composition was evaluated by bioelectrical impedance analysis (BIA) and laboratory tests were supplemented by analysis of plasma circulating irisin. Results: A negative correlation between irisin concentration and both CRP and TNF-α was recorded (R = −0.362 and R = −0.243; p < 0.05). Irisin concentration positively correlated with EF% (R = 0.253; p = 0.046) and negatively with LVESd, LVEDd and NT-proBNP (R = −0.326, −0.272, and −0.320; p < 0.05). Both low levels of circulating irisin and Capacitance of membrane (Cm) were selected as unfavorable factors affecting cachexia in CHF patients (OR = 1.39 and 34.49; p < 0.05). Combination of Cm, irisin, CRP and albumin demonstrated sensitivity of 93.3% and specificity of 85.3% (AUC = 0.949) for distinguishing between cachectic and non-cachectic CHF patients. Conclusions: Selected parameters reliably reflect cachectic conditions in CHF, and the proposed approach for cachexia based on the combined analysis of at least a few non-invasive markers could offer new opportunities for improving clinical outcomes in CHF patients.

show abstract

“…Furthermore, FNDC5 overexpression significantly improved obesity-induced myocardial inflammation, fibrosis, oxidative stress, and cardiac remodeling [ 38 ]. Not only animal experiments, but some clinical studies also revealed that serum levels of irisin were decreased in subjects with heart failure, especially in those with reduced ejection fraction [ 12 , 39 ]. These findings show that irisin could be regarded as a promising biomarker and potential therapeutic target for cardiac injuries and remodeling.…”

Section: Discussionmentioning

confidence: 99%

Irisin as a Potential Biomarker Associated with Myocardial Injuries in Patients with Severe Hypothyroidism

Yao

Ding

Gao

et al. 2021

International Journal of Endocrinology

View full text Add to dashboard Cite

Objective. Irisin, a novel myokine, has recently been considered to produce a cardioprotective effect. Potential biomarkers for myocardial injuries in patients with severe hypothyroidism have yet to be identified. We aimed to investigate whether serum irisin may serve as a promising biomarker for early detecting the myocardial injuries in patients with severe hypothyroidism. Methods. This cross-sectional study comprised 25 newly diagnosed drug-naive patients with severe primary hypothyroidism and 17 age- and sex-matched healthy controls. Circulating irisin levels and cardiac magnetic resonance (CMR) were evaluated in each participant. Left ventricular (LV) myocardial injuries were detected by CMR-based T1 mapping technique using a modified look-locker inversion recovery (MOLLI) sequence, which is quantified as native T1 values. Results. Compared with healthy controls, the severe hypothyroidism group had significantly lower levels of serum irisin, especially those with pericardial effusion ( P < 0.05 ). The severe hypothyroidism subjects exhibited lower peak filling rates (PFRs) and higher native myocardial T1 values than controls ( P < 0.05 ). Additionally, the ROC analysis displayed that the sensitivity and specificity of serum irisin for diagnosing pericardial effusion in patients with severe hypothyroidism were 73.3% and 100.0%, respectively. The AUC was 0.920 (0.861–1.000) ( P < 0.001 ). The cutoff value was 36.94 ng/mL. Moreover, the results in subgroup analysis revealed that the native T1 values of the low-irisin group were significantly higher than that of the high-irisin group ( P < 0.05 ). According to multivariate linear regression analysis, serum irisin concentrations were negatively and independently correlated with native myocardial T1 values after adjustment for age, sex, and other conventional confounding factors (β = −1.473, P < 0.05 ). Conclusions. Irisin may be a potential biomarker for predicting myocardial injuries in patients with severe hypothyroidism.

show abstract

Serum irisin level in myocardial infarction patients with or without heart failure

Cited by 34 publications

References 54 publications

Adipokines, Myokines, and Cardiokines: The Role of Nutritional Interventions

Adipokines, Myokines, and Cardiokines: The Role of Nutritional Interventions

Electrical and Hormonal Biomarkers in Cachectic Elderly Women with Chronic Heart Failure

Irisin as a Potential Biomarker Associated with Myocardial Injuries in Patients with Severe Hypothyroidism

Contact Info

Product

Resources

About